Prostate Cancer Clinical Trial
A Study of FT-7051 in Men With MCRPC
This is a Phase 1, open-label study that will evaluate the safety and tolerability of FT-7051 and determine the recommended Phase 2 dose (RP2D) as well as pharmacokinetics (PK), preliminary anti-tumor activity, and pharmacodynamics (PD) of FT-7051 in men with metastatic castration-resistant prostate cancer who have progressed despite prior therapy and had been treated with at least one potent anti-androgen therapy.
The starting dose, 25 mg once daily (QD), of FT-7051 administered discontinuously (21 days on/7 days off) in 28-day cycles.
Signed informed consent
Diagnosis of progressive metastatic castration-resistant prostate cancer (mCRPC)
Previously failed at least one potent anti-androgen therapy
Castrate levels of serum testosterone
ECOG performance status 0-2
Adequate bone marrow function
Adequate kidney, heart and liver function
Prior solid organ transplant
Prior treatment with small molecules including chemotherapy, antibody, or other experimental anticancer therapeutic within 4 weeks of first dose of study treatment
Prior radiation therapy within 4 weeks prior to initiation of study treatment (including radiofrequency ablation)
Prior androgen antagonist therapy (enzalutamide, apalutamide, abiraterone acetate, or darolutamide) within 2 weeks
Prior radium-223 therapy within 6 weeks
Symptomatic, untreated or actively progressing central nervous system (CNS) metastasis
Unstable or severe, uncontrolled medical condition (e.g., unstable cardiac function, unstable pulmonary condition including pneumonitis and/or interstitial lung disease, uncontrolled diabetes, active or uncontrolled infection requiring systemic therapy) or any important medical illness or abnormal laboratory finding that would, in the Investigator's judgement, increase the risk to the patient associated with participation in the study
Concomitant medications that cause Torsades de Pointes that have not reached steady state before first dose of the study drug
Concomitant medications that are strong inhibitors or inducers of CYP3A4 or an inhibitor of P-gp
History of infection with human immunodeficiency virus (HIV)
Active infection with hepatitis B, or hepatitis C virus
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 8 Locations for this study
Scottsdale Arizona, 85258, United States
Aurora Colorado, 80045, United States
Chicago Illinois, 60611, United States
Baltimore Maryland, 21201, United States
Saint Louis Missouri, 63110, United States
New York New York, 10029, United States
Durham North Carolina, 27710, United States
Myrtle Beach South Carolina, 29572, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.